	US 12,343,404 B2
	Ligand-targeted cell conjugate (LTCC)-based anti-tumor immune cell
Zhaohui Huang, Jiangsu (CN); Zhimeng Wu, Jiangsu (CN); Liang Gong, Jiangsu (CN); and Yanchun Li, Jiangsu (CN)
Assigned to AFFILIATED HOSPITAL OF JIANGNAN UNIVERSITY, Jiangsu (CN)
Filed by AFFILIATED HOSPITAL OF JIANGNAN UNIVERSITY, Jiangsu (CN); and JIANGNAN UNIVERSITY, Jiangsu (CN)
Filed on Dec. 15, 2021, as Appl. No. 17/551,412.
Claims priority of application No. 202011578778.2 (CN), filed on Dec. 28, 2020.
Prior Publication US 2022/0202949 A1, Jun. 30, 2022
Int. Cl. A61K 47/69 (2017.01); A61K 40/15 (2025.01); A61K 40/42 (2025.01); A61K 47/68 (2017.01); A61P 35/00 (2006.01); C12N 5/0783 (2010.01)

CPC A61K 47/6901 (2017.08) [A61K 40/15 (2025.01); A61K 40/4204 (2025.01); A61K 47/6851 (2017.08); A61P 35/00 (2018.01); C12N 5/0646 (2013.01); A61K 2239/31 (2023.05); A61K 2239/38 (2023.05)]

4 Claims

1. A ligand-targeted cell conjugate (LTCC)-based anti-tumor immune cell, characterized in that an immune cell modified with a bioorthogonal reactive group on a surface and a targeting ligand modified with a bioorthogonal reactive pairing group on the surface are correspondingly connected through a bioorthogonal reaction, to form a targeting immune cell, which is conjugated with the targeting ligand on the surface, wherein the targeting ligand performs specific recognition and is connected with a highly expressed receptor on the surface of the tumor cell;

wherein the targeting ligand is Nanobody 7D12 (Nb 7D12);

the targeting immune cell is Natural Killer cell (NK cell);

the bioorthogonal reactive group is an azide group; and

the bioorthogonal reactive pairing group is dibenzocyclooctyne (DBCO).